Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2018 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Initiates Two Pivotal Phase III Studies in Israel

HAIFA, Israel, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that Israel’s...
July 26, 2018 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Granted Key Patent in Japan for Treatment of GI Following Acute Radiation Exposure

Patent covers PLX-R18’s protection of the gastrointestinal (GI) tract from radiation exposureRecent data from Fukushima University shows PLX-R18 cells significantly increased survival and enhanced the...
July 09, 2018 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Signs Collaboration Agreement With Thermo Fisher Scientific

HAIFA, Israel, July 09, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that it has...
June 25, 2018 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem and Fukushima University Report Positive Data: PLX-R18 Increases Survival Rates and Mitigates Severe Intestinal Damage after Acute Radiation Exposure

HAIFA, Israel, June 25, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today reported positive data from...
June 19, 2018 07:00 ET | Source: Pluristem Therapeutics, Inc.

U.S. Department of Defense to Study Pluristem’s PLX-R18 for the Treatment of Mustard Gas Injuries

Studies to be funded by the U.S. NIHMarks the second project for DOD with PLX-R18 cell therapy product HAIFA, Israel, June 19, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI)...
June 14, 2018 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem to Open Weekly Market Trading at TASE Following Positive Study Results

HAIFA, Israel, June 14, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, is delighted to announce that it...
June 12, 2018 06:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Reports Positive Top-Line Results from Its Multinational Phase II Intermittent Claudication Study

PLX-PAD treatment reduced risk of revascularization and improved patients’ mobility. Study validates the design of Pluristem’s ongoing Pivotal Phase III study in Critical Limb Ischemia (CLI) HAIFA,...
June 04, 2018 06:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem to Announce Top-Line Results of Its Multinational Phase II Intermittent Claudication Study on June 12, 2018

HAIFA, Israel, June 04, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that the top-line...
May 10, 2018 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Reports Third Quarter Fiscal 2018 Corporate and Financial Highlights

HAIFA, Israel, May 10, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today reported financial results...
April 30, 2018 07:00 ET | Source: Pluristem Therapeutics, Inc.

U.S. FDA Clears Pluristem’s IND to Treat Victims Exposed to Acute Radiation

HAIFA, Israel, April 30, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that the U.S....